Stockscreener 앱 받기
491.47
5.69%
26.45
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Ins - GuruFocus
Vertex veers upwards on impressive results - The Pharma Letter
Vertex Pharmaceuticals Signals Confident Growth Beyond CF - TipRanks
Vertex’s CRISPR therapy rebounds in latest earnings - BioPharma Dive
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 - The Motley Fool
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase - Finviz
Vertex Pharmaceuticals (VRTX): Scotiabank Raises Price Target to $558 | VRTX Stock News - GuruFocus
RBC Capital Lowers Vertex Pharmaceuticals' (VRTX) Price Target | - GuruFocus
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz
Vertex Pharmaceuticals (VRTX) Analyst Maintains Rating and Raises Price Target | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says - marketscreener.com
Top Biotech Stocks To ConsiderFebruary 13th - MarketBeat
Busy with Casgevy and Journavx launches, Vertex sets ambitious $500M revenue goal for non-CF meds this year - Fierce Pharma
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Topline Grows 10% - FXDailyReport.Com
Vertex Prepares Povetacicept For APRIL/BAFF Battle - Citeline News & Insights
Agree To Purchase Vertex Pharmaceuticals At $320, Earn 4.4% Using Options - Nasdaq
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp - BioSpace
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News - GuruFocus
Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays - Insider Monkey
AI for investors - MLQ.ai
Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $577 From $572, Maintains Outperform Rating - marketscreener.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Outperform" at Oppenheimer - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Vertex Pharma Q4 2025 Earnings Results - AlphaStreet News
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts - BioSpace
Vertex Pharmaceuticals (VRTX) Receives Boosted Price Target from HC Wainwright & Co. | VRTX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts - Benzinga
11,989 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by ING Groep NV - MarketBeat
Atria Investments Inc Acquires 2,418 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highligh - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Drops After Hours — Here's Why It's Trending Tonight - Benzinga
Vertex Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Vertex Pharmaceuticals (VRTX) Reports Strong Q4 2025 Revenue Growth - GuruFocus
Vertex Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Mark Bunnage Sells 2,021 Shares - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,751 Shares of Stock - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 466 Shares of Stock - MarketBeat
Vertex Pharmaceuticals (VRTX) Reports Mixed Q4 Results with Stro - GuruFocus
How Vertex Pharmaceuticals Incorporated stock responds to policy changesOptions Play & Daily Stock Momentum Reports - mfd.ru
VRTX: 2025 delivered robust growth and diversification, with 2026 set for further expansion and innovation - TradingView
Earnings call transcript: Vertex Q4 2025 sees revenue growth, EPS miss - Investing.com
Vertex Pharmaceuticals (NASDAQ:VRTX) CAO Sells $633,551.68 in Stock - MarketBeat
Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Surpasses Q4 Revenue Expectations - GuruFocus
Vertex Pharma Q4 revenue rises 10% YoY, but earnings miss analyst expectations - Investing.com Australia
Vertex Q4 results miss on bottom line; 2026 revenue guidance in-line - Seeking Alpha
Vertex Pharmaceuticals falls after Q4 profit miss - TradingView
Vertex Pharmaceuticals (NASDAQ:VRTX) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Vertex Pharmaceuticals's (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue - Finviz
Vertex: Q4 Earnings Snapshot - kare11.com
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q4 Revenue $3.19B, vs. FactSet Est of $3.18B - marketscreener.com
Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q4 Adjusted EPS $5.03, vs. FactSet Est of $5.11 - marketscreener.com
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q4 Adjusted EPS $5.03 per Share, vs. FactSet Est of $5.11 - marketscreener.com
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue - Yahoo Finance
Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line - Nasdaq
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
Vertex Pharma’s Precision Bet: How Vertex Is Rewriting the Rulebook for Biotech Blockbusters - AD HOC NEWS
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term - Nasdaq
12,843 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Leuthold Group LLC - MarketBeat
Rhumbline Advisers Has $175.43 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Drops After HoursHere's Why It's Trending Tonight - Bitget
Cystic Fibrosis Market to hit US$ 26.58 Billion by 2031 | Major - openPR.com
Vertex Pharmaceuticals (VRTX) Q4 Earnings Preview: Key Expectati - GuruFocus
Biotech Stocks To Add to Your WatchlistFebruary 11th - MarketBeat
Vertex Pharmaceuticals's Earnings Outlook - Benzinga
2.49%
1.39%
자본화:
|
볼륨(24시간):